Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.
Aerovate Therapeutics, a US-based pulmonary disease treatment developer backed by spinout-focused venture capital firm Osage University Partners, went public yesterday following an initial public offering that raised more than $121m.
The company issued more than 8.68 million shares priced at $14 in its upsized offering on the Nasdaq Global Market, where it has listed under the ticker symbol AVTE. Shares hit a $29.43 peak on the first day of trading and are worth $22.83 as of the…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
